SNY Stock Recent News

Shares of French drugmaker Sanofi fell as much as 16% on Friday after after hiking its research-and-development expense guidance as well as its expectations for taxes.

Sanofi on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shore up new drug development spending at its core business.

Sanofi SA, the French pharmaceutical company, has announced plans to potentially separate its consumer healthcare division by listing it on the capital markets by the end of next year. If the IPO occurs, it would be the third of its kind following GSK PLC (LSE:GSK, NYSE:GSK)'s spin-out of Haleon PLC (LSE:HLN, NYSE:HLN) and J&J's demerger of chemist shelf staples.

Sanofi (FRA: SNW), the giant healthcare company, is considering spinning off its consumer health business. In a statement, the management said it was hoping to create a separate company listed in France.

French drugmaker Sanofi said on Friday it was looking into the separate listing of its Consumer Healthcare business from the fourth quarter of next year and that it plans to boost drug development at its core business.

French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for its antibody therapy to prevent respiratory syncytial virus (RSV), a leading cause of hospitalizations in infants.

Sanofi SNY, +0.07% on Friday released positive trial results for its investigational eczema treatment, notching a win that stemmed from the company's recent dealmaking to bolster its immunology pipeline.

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI analysts wrote in a note Wednesday, as the companies team up on a therapy that's drawing growing investor interest.

Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately be a blockbuster drug.